Strategies for Transfusion of Platelets (SToP)

Stopped early · Phase 3

Conditions studied: Thrombocytopenia

In brief

To evaluate the hemostatic efficacy of a low dose platelet transfusion strategy compared to a standard dose platelet transfusion strategy.

Key facts

Study ID

NCT00420914

Run by

Hamilton Health Sciences Corporation

People needed

130

Starts

2003-10-01

Last updated by the study team

2008-05-28

Who can join

Age: 17 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with hypoproliferative thrombocytopenia who are expected to have a platelet count of ≤ 10,000/µL (10x10\^9/L) for ≥ 10 days (Note: the prophylactic platelet trigger may be higher than10,000/µL (10x10\^9/L) in some participating institutions; however, the patient will still be eligible for participation as long as they are expected to be thrombocytopenic for 10 days)
• Must be an inpatient.
• Weight between 40 and 100 kg.

You may not qualify if…

• Diagnosis of promyelocytic leukemia.
• A history or current diagnosis of immune thrombocytopenia (ITP), thrombotic thrombocytopenia (TTP), or hemolytic uremia syndrome (HUS).
• Evidence of ≥ WHO Grade 2 bleeding while being assessed for the study entry.
• Patients who will receive bedside Leukoreduced platelet transfusions.
• Patients who are pregnant.

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• McMaster University — Hamilton, Ontario, Canada
• Ottawa Health Research Institute — Ottawa, Ontario, Canada
• University Health Network — Toronto, Ontario, Canada
• Haukeland University Hospital — Bergen, Norway

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.